Abstract
Immune sera from convalescent patients have been shown to be effective in the treatment of patients infected with Severe Acute Respiratory Syndrome Virus (SARS-CoV) making passive immune therapy with human monoclonal antibodies an attractive treatment strategy for SARS. Previously, using Xenomouse (Amgen British Columbia Inc), we produced a panel of neutralizing Human monoclonal antibodies (HmAbs) that could specifically bind to the ectodomain of the SARS-CoV spike (S) glycoprotein. Some of the HmAbs were S1 domain specific, while some were not. In this study, we describe non-S1 binding neutralizing HmAbs that can specifically bind to the conserved S2 domain of the S protein. However, unlike the S1 specific HmAbs, the S2 specific HmAbs can neutralize pseudotyped viruses expressing different S proteins containing receptor binding domain sequences of various clinical isolates. These data indicate that HmAbs which bind to conserved regions of the S protein are more suitable for conferring protection against a wide range of SARS-CoV variants and have implications for generating therapeutic antibodies or subunit vaccines against other enveloped viruses.
Publication types
-
Research Support, N.I.H., Extramural
MeSH terms
-
Antibodies, Neutralizing / pharmacology*
-
Antibodies, Viral / pharmacology*
-
Antibody Affinity
-
Antibody Specificity
-
Binding Sites, Antibody
-
Cross Reactions
-
Epitope Mapping
-
HEK293 Cells
-
Humans
-
Membrane Glycoproteins / antagonists & inhibitors*
-
Membrane Glycoproteins / genetics
-
Membrane Glycoproteins / immunology
-
Neutralization Tests
-
Protein Binding
-
Protein Structure, Tertiary
-
Recombinant Proteins / antagonists & inhibitors
-
Recombinant Proteins / genetics
-
Recombinant Proteins / immunology
-
Severe Acute Respiratory Syndrome / immunology
-
Severe Acute Respiratory Syndrome / prevention & control
-
Severe acute respiratory syndrome-related coronavirus / drug effects*
-
Severe acute respiratory syndrome-related coronavirus / genetics
-
Severe acute respiratory syndrome-related coronavirus / immunology
-
Spike Glycoprotein, Coronavirus
-
Transfection
-
Viral Envelope Proteins / antagonists & inhibitors*
-
Viral Envelope Proteins / genetics
-
Viral Envelope Proteins / immunology
Substances
-
Antibodies, Neutralizing
-
Antibodies, Viral
-
Membrane Glycoproteins
-
Recombinant Proteins
-
Spike Glycoprotein, Coronavirus
-
Viral Envelope Proteins
-
spike glycoprotein, SARS-CoV
-
spike protein, mouse hepatitis virus